Oncology

The FDA today granted breakthrough therapy designation to a new treatment for non-small cell lung cancer patients.

Nanotechnology and shortwave infrared light reveals small tumors and cardiovascular lesions deep inside body.

Researchers found significant improvements in overall survival and in disease-free survival in patients who received trastuzumab in addition to chemotherapy.

Cyramza (ramucirumab) was approved for treatment of patients with advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma after disease progression.

Adults aged 50 years or older who feel comfortable about aging are more likely to seek preventive health care services.

Treatment inhibits key process that enables cancer cells to multiply.

An estimated 6.9 million US adults aged 35 years and older had a combined 10.9 million self-reported smoking-attributable medical conditions in 2009.

The vaccine that prevents illness and death from pneumococcal infection also combats severe antibiotic-resistant disease in young children.

Palbociclib provides first-line systemic treatment for women with advanced or metastatic breast cancer.

The FDA today granted priority review status to a breakthrough breast cancer drug developed by Pfizer Inc.

In a retrospective study, investigators found that increases in total cholesterol and triglycerides were associated with an increased risk of biochemical recurrence in prostate cancer.

The drug combination prevents nausea and vomiting after the start of cancer chemotherapy.

The drug combination prevents nausea and vomiting after the start of cancer chemotherapy.

Brand name, patent-protected medications drive increasing costs.

Researcher urges caution in prescribing testosterone therapy in men who have not been diagnosed with hypogonadism.

Tobacco users have an increased risk of oral human papillomavirus type 16, a sexually transmitted virus that is strongly associated with cervical cancer.

Researchers in Finland are learning more about how hormones influence the risk of developing breast cancer, which may lead to a hormone-based treatment to reduce the risk of developing cancer later in life.

Parents who know about the human papillomavirus are not more likely to get their adolescent daughters vaccinated.

Patients who smoke both traditional and e-cigarettes less likely to quit than those who only smoke traditional cigarettes.

Study finds stringent eligibility criteria is creating a barrier for patient enrollment.

A new metaanalysis suggests that quitting smoking, or even reducing tobacco intake, reduces the risk of dying from prostate cancer.

Therapy significantly reduces development of secondary skin cancer.

A combination of vemurafenib (Zelboraf) and experimental drug cobimetinib significantly reduces the development of secondary skin cancer.